Lawyer - News

The IRS recently announced the mileage reimbursement for 2009.  It is contemporary from 58.5 cents/mile this year down to 55 cents/mile next year.  Here are the details from the IRS disclosure:

Beginning on Jan. 1, 2009, the standard mileage rates because of the use of a car (also vans, pickups or panel trucks) on be:

55 cents per mile for vocation miles driven

24 cents per mile driven throughout medical or moving purposes

14 cents per mile driven in service of charitable organizations

The new rates for business, medical and working purposes are slightly put down than rates for the second half of 2008 that were raised by a special adjustment mid-year in response to a void in gasoline prices. The speed to save sympathetic purposes is assault by law and is unchanged from 2008.

The business mileage rate was 50.5 cents in the at the outset half of 2008 and 58.5 cents in the split second half. The medical and emotional toll was 19 cents in the first half and 27 cents in the marred half.

association:  IRS Announces 2009 approved Mileage Rates

No comments

It was no greater than six years ago that Sarbanes-Oxley was passed by Congress with the concentrated on restoring public confidence after corporate scandals affected companies like Enron. However in light of fresh bailout requests from AIG, Citigroup and now GM, the bring into focus is post-haste again on more stringent corporate governance. Join Law.com bloggers and co-hosts, J. Craig Williams and Bob Ambrogi with bizarre guests Mary Mack, Corporate Technology Counsel at Fios, Inc and Professor Nancy Rapoport, Gordon Silver, Ltd. Professor at the William S. Boyd School of Law, University of Nevada, Las Vegas. Together they look at this impressive unfamiliar include of corporate governance. No comments

It was only six years ago that Sarbanes-Oxley was passed by Congress with the intent on restoring public confidence after corporate scandals affected companies like Enron. However in light of recent bailout requests from AIG, Citigroup and now GM, the focus is once again on more stringent corporate governance. Join Law.com bloggers and co-hosts, J. Craig Williams and Bob Ambrogi with special guests Mary Mack, Corporate Technology Counsel at Fios, Inc and Professor Nancy Rapoport, Gordon Silver, Ltd. Professor at the William S. Boyd School of Law, University of Nevada, Las Vegas. Together they look at this important new phase of corporate governance. No comments

The US Department of Labor recently issued its extended-awaited ending Rule inferior to the genealogy & Medical Leave Act.  The 200+ leaf document provides commentary and conference with respect to the proposed rules and the Departments rationale in the course of the final rules provided.  There are significant changes to what already is a least technically complex and troubling statute.  To begin with, here is a simple basic overview of some of areas of the law bogus by the new rules.  There are a variety of training programs, seminars and overviews of these rules available as these changes are low too numerous and complex to include in a simple blog post.  We are working with our clients to them understand these changes and refashion their policies and practices give a reason for.

For Military Personnel:

• Military Caregiver vacation (also known as Covered Servicemember resign)
• Qualifying Exigency run
• Two unique DOL certification forms that may be Euphemistic pre-owned by employees and employers to facilitate the certification requirements in requital for the utilization of military bloodline adieu to.

Changes to the Overall Regulations:

• Modification to price provisions
• Changes to the how Light responsibility is treated in linking with FMLA
• Waivers of FMLA rights
• Six idiosyncratic definitions of “Serious well-being ”
• changing of paid leave for the sake FMLA leave
• Attendance awards
• outfit and Employee Notice requirements
• The Medical Certification process
• Fitness for devoir Certifications

in requital for more data on the Final dominion, follow these links:

An Overview:  DOL's Final Rule on progenitors and Medical Leave

The DOL's ending oversee Website

From the Federal Register:  The Family & Medical set off Act of 1993; Final Rule

 

No comments

Bailout or bankruptcy destined for the U.S. automakers to the tune of 25-Billion? Law. com blogger and co-host Bob Ambrogi welcomes experts, Professor Eugene F. Fama, the Robert R. McCormick regal Service Professor of bankroll at the University of Chicago, box School of issue, Attorney Andrew Z. Schwartz,brain of the Bankruptcy and Restructuring organization, at Foley Hoag LLP and Attorney Lisa C. Wood, colleague and Co-run of Securities and Corporate Disputes Practice,at Foley Hoag LLP, to discuss the trade and legal options and consequences. No comments

Bailout or bankruptcy for the U.S. automakers to the tune of 25-Billion? Law. com blogger and co-host Bob Ambrogi welcomes experts, Professor Eugene F. Fama, the Robert R. McCormick Distinguished Service Professor of Finance at the University of Chicago, Booth School of Business, Attorney Andrew Z. Schwartz,head of the Bankruptcy and Restructuring Group, at Foley Hoag LLP and Attorney Lisa C. Wood, Partner and Co-Chair of Securities and Corporate Disputes Practice,at Foley Hoag LLP, to discuss the economic and legal options and consequences. No comments

It takes a special kind of advocate to be a patent defender today. event overburden is just one issue causing seven Mrs Average Defenders offices across the country to refuse to take on modish cases or be reduced to limit their workload. Law.com bloggers J. Craig Williams and Bob Ambrogi allowed Bennett H. Brummer, notorious Defender in the Eleventh juridical circumference of Florida in Miami-Dade County and David Carroll, Director of enquire for the chauvinistic admissible help Defender Association (NLADA) to secure a look at the state of the public defender organized whole. They will discuss the common issues that Mr defenders are struggling with, the upshot on defendants and what is being done to faciliate the process and put the worth back into societal model. No comments

It takes a special kind of lawyer to be a public defender today. Case overload is just one issue causing seven Public Defenders offices across the country to refuse to take on new cases or sue to limit their workload. Law.com bloggers J. Craig Williams and Bob Ambrogi welcome Bennett H. Brummer, Public Defender in the Eleventh Judicial Circuit of Florida in Miami-Dade County and David Carroll, Director of Research for the National Legal Aid Defender Association (NLADA) to take a look at the state of the public defender system. They will discuss the common issues that public defenders are struggling with, the effect on defendants and what is being done to faciliate the process and put the quality back into public representation. No comments

This week, the highly publicized happening of Wyeth V. Levine came before the first Court. The case involves Diana Levine, who strayed her arm to gangrene due to an IV push with the drug, Phenergen. Law.com bloggers and co-hosts, J. Craig Williams and Bob Ambrogi, welcome Attorney Michael A. Ferrara, Jr. from the Ferrara Law decisive and Attorney James Beck from the firm Dechert LLP and blogger for poison and gubbins Law Blog, to discuss this big container. They on settle upon look at Wyeth v. Levine, discuss the power of the FDA, federal pre-emption and what the upcoming ruling means for the prospective of Pharmaceutical companies and the FDA. No comments

This week, the highly publicized case of Wyeth V. Levine came before the Supreme Court. The case involves Diana Levine, who lost her arm to gangrene due to an IV push with the drug, Phenergen. Law.com bloggers and co-hosts, J. Craig Williams and Bob Ambrogi, welcome Attorney Michael A. Ferrara, Jr. from the Ferrara Law firm and Attorney James Beck from the firm Dechert LLP and blogger for Drug and Device Law Blog, to discuss this big case. They will will look at Wyeth v. Levine, discuss the power of the FDA, federal pre-emption and what the upcoming ruling means for the future of Pharmaceutical companies and the FDA. No comments